文献速递主动脉疾病

开窗与去分支TEVAR治疗远端主动脉弓及降主动脉病变的比较

Fenestrated versus debranching thoracic endovascular aortic repair for endovascular treatment of distal aortic arch and descending aortic lesions.
PubMed 文献 · J Vasc Surg · 2020-11-27

单中心回顾性研究比较开窗TEVAR与去分支TEVAR治疗远端主动脉弓及降主动脉病变,两组技术成功率均高且靶血管通畅率100%,去分支组手术时间更短但局部并发症更多。

要点

  • 开窗TEVAR与去分支TEVAR均获高技术成功率,靶血管中期通畅率100%。
  • 去分支TEVAR组手术时间更短,但29.4%出现去分支相关局部并发症。
  • 两组随访期再干预率无显著差异,开窗组10.5%对去分支组35.3%。

核心结论

  • 两种技术均显示优异的靶血管中期通畅率和高技术成功率。
  • 开窗TEVAR手术时间更短且避免去分支相关并发症。

研究设计与样本

  • 单中心回顾性研究,2012至2018年纳入19例开窗TEVAR和17例去分支TEVAR择期患者,排除急诊病例。

主要发现

  • 开窗组平均年龄65.8±2岁,男性58%;去分支组平均年龄68±3岁,男性82%。
  • 开窗组外周动脉疾病5/19(26%),去分支组0例(P=.049)。
  • 夹层或夹层后动脉瘤在开窗组6/19(31.6%),去分支组12/17(70.6%)(P=.04)。
  • 开窗组平均腔内手术时间191±120分钟,去分支组130±75分钟(P=NS);去分支手术时间181±97分钟。
  • 去分支组5/17(29.4%)出现去分支相关局部并发症,两组无死亡或重大卒中。

关键数值与推荐

  • 开窗组再干预2/19(10.5%),去分支组6/17(35.3%)(P=NS)。
  • 12个月免于非计划再干预率开窗组86%,去分支组81%。
  • 左锁骨下动脉支架或颈锁骨下动脉搭桥/转位一期通畅率两组均为100%。

临床怎么用

  • 开窗TEVAR可作为远端主动脉弓及降主动脉病变的替代方案,避免颈部去分支相关并发症。

局限性

  • 单中心回顾性设计,样本量小,随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cervical debranching, followed by thoracic endovascular aortic repair (TEVAR), is well-established for treating aortic arch lesions. However, total endovascular repair with fenestrated endografts has not been adequately studied. Thus, we performed a comparison of the two techniques. METHODS: The present study was a single-center, retrospective study comparing the treatment of thoracic aortic lesions with custom-made fenestrated stent-grafts (fenestrated TEVAR [fTEVAR]) with a single fenestration for the left subclavian artery (LSA), a scallop for the left carotid artery, and hybrid repair with a thoracic stent-graft and cervical debranching of the LSA. Emergency cases were excluded. RESULTS: From 2012 to 2018, 19 patients (58% male) underwent elective fTEVAR (group A) and 17 patients (82% male) underwent debranching TEVAR (dTEVAR; group B). The mean age ± standard deviation in group A was 65.8 ± 2 years and 68 ± 3 years in group B. Left carotid-subclavian bypass was performed in 15 of 17 patients (88%) and transposition of the LSA in 2 of 17 patients (12%) in group B. The two groups were comparable regarding comorbidities, except for peripheral arterial disease: 5 of 19 patients in group A (26%) and none in group B had had peripheral arterial disease (P = .049). Dissection or post-dissection aneurysm was the indication for treatment in 6 of 19 patients in the fTEVAR group (group A) and in 12 of 17 patients in the dTEVAR group (group B; 31.6% vs 70.6%; P = .04). The indication for the remaining patients was a degenerative aortic aneurysm. Technical success was achieved in all cases, except for one case of dTEVAR owing to a type Ia endoleak. The mean endovascular operative time was 191 ± 120 minutes for fTEVAR and 130 ± 75 minutes for dTEVAR (P = NS). The mean operative time for the debranching procedure was 181 ± 97 minutes. No deaths or major strokes had occurred in the early postoperative period (30 days). Of the 17 patients in group B, 5 (29.4%) had experienced a local complication related to the debranching procedure. The mean follow-up was 14.6 ± 2 months for group A and 17 ± 2 months for group B. Of the 19 patients in group A and 17 patients in group B, 2 (10.5%) and 6 (35.3%) had required an unplanned reintervention related to the thoracic stent-graft during the follow-up period, respectively (P = NS). The estimated freedom from unplanned reintervention at 12 months was 86% for group A and 81% for group B. Primary patency of the LSA stent-graft or the carotid-subclavian bypass/transposition was 100% in both groups. CONCLUSIONS: Both techniques showed excellent midterm patency rates for the target vessel and high technical success rate. The operation times were shorter for the fTEVAR group and complications related to the debranching procedure were avoided.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Konstantinou N, Kölbel T, Debus ES, et al. Fenestrated versus debranching thoracic endovascular aortic repair for endovascular treatment of distal aortic arch and descending aortic lesions. J Vasc Surg. 2020. PMID: 33253872. doi:10.1016/j.jvs.2020.10.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。